Innovent Biologics, Inc. announced revenue results for the fourth quarter of 2022. In the fourth quarter of 2022, the Company achieved a total product revenue of approximately RMB 1 billion.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
37.7 HKD | -1.95% | -4.19% | -11.81% |
Mar. 21 | Innovent Biologics' Loss Narrows in 2023 as Revenue Grows | MT |
Mar. 20 | Innovent Biologics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.81% | 7.97B | |
+0.44% | 90.27B | |
+9.61% | 44.05B | |
-16.85% | 31.45B | |
+44.74% | 23.35B | |
-8.46% | 16.72B | |
-25.92% | 15.09B | |
-9.50% | 12.82B | |
-7.57% | 11.95B | |
+0.07% | 8.71B |
- Stock
- Equities
- Stock Innovent Biologics, Inc. - Hong Kong S.E.
- News Innovent Biologics, Inc.
- Innovent Biologics, Inc. Announces Revenue Results for the Fourth Quarter of 2022